Chronic postsurgical pain in Europe: An observational study

BACKGROUNDChronic postsurgical pain (CPSP) is an important clinical problem. Prospective studies of the incidence, characteristics and risk factors of CPSP are needed. OBJECTIVESThe objective of this study is to evaluate the incidence and risk factors of CPSP. DESIGNA multicentre, prospective, obser...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of anaesthesiology 2015-10, Vol.32 (10), p.725-734
Hauptverfasser: Fletcher, Dominique, Stamer, Ulrike M, Pogatzki-Zahn, Esther, Zaslansky, Ruth, Tanase, Narcis Valentin, Perruchoud, Christophe, Kranke, Peter, Komann, Marcus, Lehman, Thomas, Meissner, Winfried
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUNDChronic postsurgical pain (CPSP) is an important clinical problem. Prospective studies of the incidence, characteristics and risk factors of CPSP are needed. OBJECTIVESThe objective of this study is to evaluate the incidence and risk factors of CPSP. DESIGNA multicentre, prospective, observational trial. SETTINGTwenty-one hospitals in 11 European countries. PATIENTSThree thousand one hundred and twenty patients undergoing surgery and enrolled in the European registry PAIN OUT. MAIN OUTCOME MEASURESPain-related outcome was evaluated on the first postoperative day (D1) using a standardised pain outcome questionnaire. Review at 6 and 12 months via e-mail or telephonic interview used the Brief Pain Inventory (BPI) and the DN4 (Douleur Neuropathique four questions). Primary endpoint was the incidence of moderate to severe CPSP (numeric rating scale, NRS ≥3/10) at 12 months. RESULTSFor 1044 and 889 patients, complete data were available at 6 and 12 months. At 12 months, the incidence of moderate to severe CPSP was 11.8% (95% CI 9.7 to 13.9) and of severe pain (NRS ≥6) 2.2% (95% CI 1.2 to 3.3). Signs of neuropathic pain were recorded in 35.4% (95% CI 23.9 to 48.3) and 57.1% (95% CI 30.7 to 83.4) of patients with moderate and severe CPSP, respectively. Functional impairment (BPI) at 6 and 12 months increased with the severity of CPSP (P 
ISSN:0265-0215
1365-2346
DOI:10.1097/EJA.0000000000000319